NCT05713851View on ClinicalTrials.gov

Dapaglifozin to Avoid Acute Kindey Injury (AKI) to Chronic Kidney Disease (CKD) Transition: DAKI-CKD Study

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

January 1, 2023

Primary Completion Date

December 1, 2024

Study Completion Date

January 1, 2025

Conditions
AKI - Acute Kidney InjuryBiomarkersTransition to CKDCKD
Interventions
DRUG

Dapagliflozin

dapagliflozin is given for 21 days vs standard of care

Trial Locations (1)

14080

RECRUITING

Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City

All Listed Sponsors
collaborator

Olynka Vega Vega

UNKNOWN

collaborator

Noemi del Toro Cisneros

UNKNOWN

collaborator

Miguel Ángel Martínez Rojas

UNKNOWN

lead

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

OTHER